These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 21079066)
21. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face. Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569 [TBL] [Abstract][Full Text] [Related]
22. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. Senise JF; Castelo A; Martínez M AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356 [TBL] [Abstract][Full Text] [Related]
23. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D; J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942 [TBL] [Abstract][Full Text] [Related]
24. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C; HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724 [TBL] [Abstract][Full Text] [Related]
25. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
26. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report. Parruti G; Toro GM BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141 [TBL] [Abstract][Full Text] [Related]
27. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866 [TBL] [Abstract][Full Text] [Related]
28. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. McComsey G AIDS Rev; 2002; 4(3):140-7. PubMed ID: 12416448 [TBL] [Abstract][Full Text] [Related]
29. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G; AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350 [TBL] [Abstract][Full Text] [Related]
30. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up. Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868 [TBL] [Abstract][Full Text] [Related]